Arega D (2007). Epidemiology and Drug Resistance Pattern of Mycobacterial Isolates among HIV positive and HIV negative TB patients using Conventional and Molecular Methods in South east Ethiopia. Addis Ababa University.

Byrd RB, Horn BR, Solomon DA, Griggs GA (1979). Toxic effects of isoniazid in tuberculosis chemoprophylaxis: role of biochemical monitoring in 1,000 patients. JAMA 241:1239-1241.
Crossref

Devi SB, Naorem S, Singh TJ, Singh KB, Prasad L, Devi TS (2005). HIV and TB coinfection. J. Ind. Acad. Clin. Med. 6:220-223.

D'Souza R, Foster GR (2004). Diagnosis and treatment of chronic hepatitis B. J. R. Soc. Med. 97:318-321.
Crossref

FMoH (2010). Implementation Guidelines for TB/HIV collaborative activities in Ethiopia. National TB/HIV working group, Addis Ababa, Ehiopia.

Hennessey KA, Kim AA, Griffin V, Collins NT, Weinbaum CM, Sabin K (2009). Prevalence of infection with hepatitis B and C viruses and co-infection with HIV in three jails: a case for viral hepatitis prevention in jails in the United States. J. Urban Health 86:93-105.
Crossref

Iser DM, Sasadeusz JJ (2008). Current treatment of HIV/hepatitis B virus coinfection. J. Gastroenterol. Hepatol. 23:699-706.
Crossref

Kumar P, Sharma N, Sharma N, Patnaik S (2002). Clinical profile of tuberculosis in patients with HIV infection/AIDS. Indian J. Chest Dis. Allied Sci. 44:159-164.
Pubmed

Marzuki O, Fauzi A, Ayoub S, Kamarul Imran M (2008). Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis in Malaysia. Singap. Med. J. 49:688.
Pubmed

Padmapriyadarsini C, Chandrabose J, Victor L, Hanna L, Arunkumar N, Swaminathan S (2006). Hepatitis B or hepatitis C co-infection in individuals infected with human immunodeficiency virus and effect of anti-tuberculosis drugs on liver function. J. Postgrad. Med. 52:92.
Pubmed

Sharma S, Mohan A, Kadhiravan T (2005). HIV-TB co-infection: epidemiology, diagnosis & management. Indian J. Med. Res.121: 550-567.
Pubmed

Sirinak C, Kittikraisak W, Pinjeesekikul D, Charusuntonsri P, Luanloed P, Srisuwanvilai LO, Nateniyom S, Akksilp S, Likanonsakul S, Sattayawuthipong W (2008). Viral hepatitis and HIV-associated tuberculosis: risk factors and TB treatment outcomes in Thailand. BMC Public Health 8:245.
Crossref

Solomon SS, Srikrishnan AK, Mehta SH, Vasudevan CK, Murugavel KG, Thamburaj E, Anand S, Kumar MS, Latkin C, Solomon S (2008). High prevalence of HIV, HIV/hepatitis C virus co-infection and risk behaviors among IDUs in Chennai, India: a cause for concern. J. Acquir. Immune Defic. Syndr. 49(3):327-332.
Crossref

Sterling RK, Sulkowski MS(2004) Hepatitis C virus in the setting of HIV or hepatitis B virus coinfection. Seminars in liver disease, 2004. Copyright© 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA., pp.61-68.

Sy T, Jamal MM (2006). Epidemiology of hepatitis C virus (HCV) infection. Int. J. Med. Sci. 3:41.
Crossref

UNAIDS (2009). AIDS epidemic update 2009. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO).

Wajiso K (2003). Assessment of Hiv Sero-Prevalence among Registered Tuberculosis Patients in Arsi Zone. Addis Ababa University.

WHO (World Health Organization) (2011). WHO Report, Global Tuberculosis Control, 2011. Available on: http://whqlibdoc. who. int/publications/2010/978924156406 9_eng. pdf.

WHO (World Health Organization) (2012). WHO report, Global Tuberculosis control, 2012. Available at www.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf

WHO Media Center/ HIV/AIDS (2014). Available on http://www.who.int/mediacentre/factsheets/ fs360/en/ June 3, 2015.

Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D (2003). Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am. J. Respir. Crit. Care Med. 167:1472-1477.
Crossref